trans-Activation of PPARα and Induction of PPARα Target Genes by Perfluorooctane-Based Chemicals

Peroxisome proliferator-activated receptors (PPARs) are liganddependent transcription factors that activate target genes involved in lipid metabolism, energy homeostasis, and cell differentiation in responsetodiversecompounds,includingenvironmentalchemicals. The liver-expressed receptor PPARa mediates peroxisome proliferative responses associated with rodent hepatocarcinogenesis.Previous studies haveestablished that certain perfluorooctanesulfonamide-based chemicals (PFOSAs) alter lipid metabolism, are hepatic peroxisome proliferators, and induce hepatocellular adenoma formation in rodents, suggesting that they activate PPARa. The present study investigates this question and characterizes the activation of mouse and human PPARa by PFOSAs. Perfluorooctanesulfonate(PFOS),anend-stagemetabolitecommontoseveral PFOSAs,wasfoundtoactivatebothmouseandhumanPPARaina COS-1 cell-based luciferase reporter trans-activation assay. Halfmaximal activation (EC50) occurred at 13‐15 mM PFOS, with no significant difference in the responsiveness of mouse and human PPARa. Mouse and human PPARa were activated by perfluorooctanesulfonamide (FOSA) over a similar concentration range; however, cellular toxicity precluded an accurate determination of EC50 values. Studies of 2-N-ethylperfluorooctanesulfonamido ethanol were less informative due to its insolubility. These findings were verified in an FAO rat hepatoma cell line that stably expresses PPARa, where the endogenous PPARa target genes peroxisomal bifunctionalenzymeandperoxisomal3-ketoacyl-CoAthiolasewere activatedupto � 10‐20-foldbyPFOSandFOSA.Theinteractionsof PPARawith PFOS and FOSA, and the potential of these chemicals for activation of unique sets of downstream target genes, may help explain the diverse biological effects exhibited by PFOSAs and may aid in the evaluation of human and environmental risks associated

[1]  D. Waxman,et al.  Activation of PPARα and PPARγ by Environmental Phthalate Monoesters , 2003 .

[2]  B. Spiegelman,et al.  Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: ending the heartache. , 2000, The Journal of clinical investigation.

[3]  J. Trosko,et al.  Inhibition of gap junctional intercellular communication by perfluorinated fatty acids is dependent on the chain length of the fluorinated tail , 1998, International journal of cancer.

[4]  J. Mandel,et al.  Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. , 1999, Journal of occupational and environmental medicine.

[5]  W. Wahli,et al.  PPARα Structure-Function Relationships Derived from Species-Specific Differences in Responsiveness to Hypolipidemic Agents , 1997, Biological chemistry.

[6]  G. Olsen,et al.  Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  E. K. Maloney,et al.  trans-Activation of PPARalpha and PPARgamma by structurally diverse environmental chemicals. , 1999, Toxicology and applied pharmacology.

[8]  K. Andersson,et al.  The effects of perfluoro-octanoic acid on hepatic peroxisome proliferation and related parameters show no sex-related differences in mice. , 1992, The Biochemical journal.

[9]  D. Waxman,et al.  Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. , 1998, Cancer research.

[10]  Jasmine Chen,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  David J. Waxman,et al.  trans-activation of PPARα and PPARγ by structurally diverse environmental chemicals , 1999 .

[12]  J. Peters,et al.  Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. , 1997, Carcinogenesis.

[13]  C. Elcombe,et al.  Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. , 2003, Toxicology.

[14]  J. Peters,et al.  Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. , 1998, Journal of the National Cancer Institute.

[15]  R. Schnellmann,et al.  Perfluorooctane sulfonamide: a structurally novel uncoupler of oxidative phosphorylation. , 1990, Biochimica et biophysica acta.

[16]  E. Ros,et al.  Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver , 2002, Clinical pharmacology and therapeutics.

[17]  B. Spiegelman,et al.  Peroxisome proliferator–activated receptor γ ligands and atherosclerosis: ending the heartache , 2000 .

[18]  A. Starkov,et al.  Structural determinants of fluorochemical-induced mitochondrial dysfunction. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[19]  D. Waxman,et al.  Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[20]  J. Giesy,et al.  Global distribution of perfluorooctane sulfonate in wildlife. , 2001, Environmental science & technology.

[21]  D. Waxman,et al.  Elevated basal expression of liver peroxisomal beta-oxidation enzymes and CYP4A microsomal fatty acid omega-hydroxylase in STAT5b(-/-) mice: cross-talk in vivo between peroxisome proliferator-activated receptor and signal transducer and activator of transcription signaling pathways. , 2002, Toxicology and applied pharmacology.

[22]  A. Seacat,et al.  Interactions of fluorochemicals with rat liver fatty acid-binding protein. , 2002, Toxicology.

[23]  R. Evans,et al.  Activators of the nuclear receptor PPARgamma enhance colon polyp formation. , 1998, Nature medicine.

[24]  J. Ward,et al.  Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ) , 2000, Molecular and Cellular Biology.

[25]  J. Peters,et al.  Mechanism of Action of the Nongenotoxic Peroxisome Proliferators: Role of the Peroxisome Proliferator-Activated Receptor α , 1998 .

[26]  M. Gerritsen,et al.  Peroxisome Proliferator-activated Receptor γ Ligands Are Potent Inhibitors of Angiogenesis in Vitro and in Vivo * , 1999, The Journal of Biological Chemistry.

[27]  B. Lake.  Peroxisome proliferation: current mechanisms relating to nongenotoxic carcinogenesis. , 1995, Toxicology letters.

[28]  T. Suga,et al.  Induction of Cytochrome P-450 and Peroxisome Proliferation in Rat Liver by Perfluorinated Octane Sulphonic Acid (PFOS) , 1987 .

[29]  E. Lock,et al.  Biochemical mechanisms of induction of hepatic peroxisome proliferation. , 1989, Annual review of pharmacology and toxicology.

[30]  O. Spydevold,et al.  The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. , 1992, Biochimica et biophysica acta.

[31]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  K. Griffin,et al.  A single amino acid change in the mouse peroxisome proliferator-activated receptor alpha alters transcriptional responses to peroxisome proliferators. , 1995, Molecular pharmacology.

[33]  S Subramani,et al.  Characterization of protein-DNA interactions within the peroxisome proliferator-responsive element of the rat hydratase-dehydrogenase gene. , 1993, The Journal of biological chemistry.

[34]  C. Dive,et al.  Non-genotoxic hepatocarcinogenesis in vitro: the FaO hepatoma line responds to peroxisome proliferators and retains the ability to undergo apoptosis. , 1993, Journal of cell science.

[35]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[36]  K. Hansen,et al.  Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. , 2001, Environmental science & technology.

[37]  K. Wallace,et al.  Perfluorooctanoate, perflourooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis. , 2002, Toxicology letters.

[38]  K. Griffin,et al.  Peroxisome proliferator activated receptor-alpha expression in human liver. , 1998, Molecular pharmacology.

[39]  M. Jimenez-Linan,et al.  Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.

[40]  Nathan M. Bass,et al.  Interactions of flurochemicals with rat liver fatty acid-binding protein , 2002 .

[41]  M. Weiss,et al.  Selective isolation of stable and unstable dedifferentiated variants from a rat hepatoma cell line , 1982, Journal of cellular physiology.

[42]  J. Corton,et al.  Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. , 2000, Annual review of pharmacology and toxicology.

[43]  J Auwerx,et al.  The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. , 1996, Biochimica et biophysica acta.

[44]  P Fenner-Crisp,et al.  Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? , 1998, Regulatory toxicology and pharmacology : RTP.